Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
642 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT03338790 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer(CheckMate 9KD) | completed | Phase 2 | 292 | Bristol-Myers SquibbINDUSTRY | 11 | Jan 27, 2026 |
| clinicaltrials |
| NCT06487156 | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 404 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05136677 | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants(CheckMate 6DW) | completed | Phase 2 | 102 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT03994601 | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | completed | Phase 1 / Phase 2 | 219 | Bristol-Myers SquibbINDUSTRY | 7 | Jan 20, 2026 | clinicaltrials |
| NCT06163053 | A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home | completed | — | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05209295 | A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies | terminated | Phase 1 | 2 | Bristol-Myers SquibbINDUSTRY | 5 | Jan 12, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT05002569 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma(RELATIVITY-098) | terminated | Phase 3 | 1,093 | Bristol-Myers SquibbINDUSTRY | 25 | Jan 8, 2026 | clinicaltrials |
| NCT07141563 | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC | completed | — | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT04349267 | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Bristol-Myers SquibbINDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05413044 | A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register | completed | — | 140,706 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05421442 | A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database(DANBIO) | completed | — | 38,396 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06452329 | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer | completed | — | 260 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT05134948 | A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors(RELATIVITY 059) | completed | Phase 1 / Phase 2 | 24 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT01838512 | Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) | active not recruiting | — | 2,555 | Bristol-Myers SquibbINDUSTRY | 6 | Dec 2, 2025 | clinicaltrials |
| NCT07256015 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | recruiting | — | 200 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04500535 | A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy(LIST) | completed | — | 535 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04196452 | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) | active not recruiting | — | 10 | Bristol-Myers SquibbINDUSTRY | 0 | Nov 20, 2025 | clinicaltrials |
| NCT02743494 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer(CheckMate 577) | completed | Phase 3 | 794 | Bristol-Myers SquibbINDUSTRY | 31 | Nov 18, 2025 | clinicaltrials |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 356 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT03656718 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | completed | Phase 1 / Phase 2 | 139 | Bristol-Myers SquibbINDUSTRY | 12 | Nov 12, 2025 | clinicaltrials |
| NCT07091695 | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | completed | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread(CheckMate142) | completed | Phase 2 | 385 | Bristol-Myers SquibbINDUSTRY | 8 | Nov 6, 2025 | clinicaltrials |
| NCT06345183 | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | completed | — | 327 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY | 33 | Oct 30, 2025 | clinicaltrials |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 320 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 22, 2025 | clinicaltrials |
| NCT07215962 | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% | active not recruiting | — | 300 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 332 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 9, 2025 | clinicaltrials |
| NCT06352528 | A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment | completed | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | terminated | Phase 1 | 56 | Bristol-Myers SquibbINDUSTRY | 9 | Sep 25, 2025 | clinicaltrials |
| NCT03446040 | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | terminated | Phase 1 / Phase 2 | 92 | Bristol-Myers SquibbINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT04149574 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)(CheckMate 7G8) | terminated | Phase 3 | 13 | Bristol-Myers SquibbINDUSTRY | 16 | Sep 16, 2025 | clinicaltrials |
| NCT03195478 | A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 37 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT05577715 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 6 | Sep 4, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT05162443 | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | approved for marketing | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT06163040 | A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | completed | — | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials